GC
PCVX icon

Guggenheim Capital’s Vaxcyte PCVX Stock Holding History

Guggenheim Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
38,908
+1,697
+5% +$92.2K 0.01% 691
2026
Q1 		$2.16M Buy
37,211
+2,710
+8% +$147K 0.02% 678
2025
Q4 		$1.59M Sell
34,501
-934
-3% -$41.8K 0.01% 748
2025
Q3 		$1.28M Sell
35,435
-107
-0.3% -$3.54K 0.01% 835
2025
Q2 		$1.16M Buy
35,542
+7,536
+27% +$247K 0.01% 833
2025
Q1 		$1.06M Buy
28,006
+1,556
+6% +$124K 0.01% 859
2024
Q4 		$2.17M Sell
26,450
-3,350
-11% -$333K 0.02% 625
2024
Q3 		$3.41M Sell
29,800
-224
-0.7% -$20.2K 0.02% 650
2024
Q2 		$2.27M Sell
30,024
-1,448
-5% -$98.6K 0.02% 772
2024
Q1 		$2.15M Buy
31,472
+3,915
+14% +$271K 0.02% 857
2023
Q4 		$1.73M Sell
27,557
-2,729
-9% -$142K 0.01% 903
2023
Q3 		$1.54M Buy
30,286
+1,225
+4% +$60.4K 0.01% 909
2023
Q2 		$1.45M Buy
29,061
+4,672
+19% +$221K 0.01% 992
2023
Q1 		$914K Buy
+24,389
New +$1.03M 0.01% 1227

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Guggenheim Capital's PCVX Position: Q2 2026 in Review

Guggenheim Capital increased its Vaxcyte (PCVX) stake by 4.6% in Q2 2026, buying an estimated $92.2K and bringing the position to 38,908 shares worth $2.26M. The position accounts for 0.01% of the portfolio, ranked #691.

Guggenheim Capital first reported a position in PCVX in Q1 2023 and has held it in 14 quarters since. The position peaked at $3.41M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Guggenheim Capital held 38,908 shares of Vaxcyte worth $2.26M as of Q2 2026.
  • Guggenheim Capital bought 1,697 Vaxcyte shares in Q2 2026, an estimated $92.2K.
  • Vaxcyte made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #691 holding.
  • Guggenheim Capital first reported a position in Vaxcyte in Q1 2023 and has held it in 14 quarters since.
  • Guggenheim Capital's Vaxcyte position peaked at $3.41M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.